Is Compounded Semaglutide Safe? What You Need to Know

Compounding is the practice of a licensed pharmacist preparing a customized medication for a specific patient — for example, combining or altering ingredients to meet a need that an FDA-approved product can't. It's a long-standing, legitimate part of pharmacy. What it is not is mass manufacturing of a copy of a brand-name drug.

Semaglutide is the active ingredient in Novo Nordisk's FDA-approved products: Ozempic and Rybelsus (approved for type 2 diabetes) and Wegovy (approved for chronic weight management in eligible adults and, per its label, certain adolescents). "Compounded semaglutide" refers to semaglutide prepared by a compounding pharmacy rather than purchased as one of those branded products.

The critical fact to internalize, in the FDA's own framing: compounded drugs are not FDA-approved, which means the agency does not verify their safety, effectiveness, or quality before patients receive them. That is a structural feature of compounding, not a defect of any one pharmacy. It's why the rest of this article focuses on how to evaluate the source rather than on a yes/no verdict.

Demand for GLP-1 drugs outstripped supply. Beginning in 2022, the FDA listed semaglutide products on its official drug shortage database. Under the Federal Food, Drug, and Cosmetic Act, when a drug is on the FDA shortage list, compounding pharmacies have more latitude to prepare a compounded version of an otherwise commercially available drug — this is the legal mechanism that opened the door to widespread compounded semaglutide sold through telehealth platforms.

That window narrowed. In February 2025, the FDA announced that the semaglutide shortage was resolved and removed it from the shortage list, setting enforcement timelines that differed for 503A pharmacies and 503B outsourcing facilities. The practical effect: the broad legal basis many telehealth companies relied on to offer compounded semaglutide contracted, and the conditions under which compounding is permitted reverted to the narrower rules in sections 503A and 503B of the Act.

This matters for readers because the market shifted quickly. Some providers moved patients toward branded products or manufacturer-direct programs (for example, Novo Nordisk's NovoCare pharmacy and Eli Lilly's LillyDirect, which dispense FDA-approved medications), while others continued offering compounded options under specific exceptions (such as a documented clinical need for a customized formulation). If a provider is still offering compounded semaglutide, it is fair — and important — to ask on what legal basis.

Not all compounding pharmacies are regulated the same way. Two sections of the FD&C Act define two categories, and the difference is one of the most useful things a consumer can understand.

503A pharmacies compound medications for an individual patient based on a specific prescription. They are overseen primarily by state boards of pharmacy and are expected to follow United States Pharmacopeia (USP) compounding standards. They are not required to follow federal Current Good Manufacturing Practice (CGMP) the way a drug manufacturer is.

503B outsourcing facilities are a category created by the Drug Quality and Security Act of 2013 (after the 2012 NECC meningitis outbreak that killed dozens). A 503B facility registers with the FDA, is subject to FDA inspection, and must comply with CGMP. It can compound larger batches without a patient-specific prescription for each unit. In general, a product from a 503B facility has been made under a more rigorous, federally inspected quality system than one from a 503A pharmacy — though 503B status alone is not a guarantee about any individual lot.

For a reader, the takeaway is concrete: ask whether your compounded medication comes from a 503A or 503B facility, and ask for the pharmacy's name so you can confirm its licensure and inspection history with the relevant state board or the FDA's outsourcing-facility registry.

These are documented concerns the FDA has raised, framed as agency findings rather than predictions about any individual:

• Dosing errors. The FDA has received reports of adverse events, including overdoses, when patients measure and self-administer compounded semaglutide from multi-dose vials using syringes — a different process than a prefilled pen. Errors of 5x to 20x the intended dose have been reported in some cases, leading to nausea, vomiting, and other effects requiring care.
• Salt forms that are not the approved active ingredient. The FDA has specifically warned that semaglutide sodium and semaglutide acetate are salt forms that differ from the semaglutide base used in approved products, and that the agency is not aware of any basis for compounding with these salts. A product compounded from a salt form is not equivalent to the approved drug.
• Sourcing of active ingredient. Some active pharmaceutical ingredient (API) has been sourced from facilities the FDA has not inspected, including overseas suppliers, raising quality and purity questions.
• Unknown impurities and potency variation. Because compounded products are not subject to pre-market FDA testing, potency and purity can vary between pharmacies and lots unless the pharmacy performs and documents independent testing.
• Counterfeit and illegal online sellers. The FDA and state boards have warned about websites selling "semaglutide" without a prescription, marketed as "research chemicals" or "not for human consumption." These are outside the legal compounding framework entirely and should be treated as unsafe by default.

Standalone rule of thumb: a legitimate compounded medication always involves a licensed prescriber, a valid prescription, and a U.S.-licensed pharmacy you can name and verify. If any of those three is missing, stop.

It's important to separate the evidence for the molecule from the evidence for compounded versions of it.

The FDA-approved products have been studied in large randomized trials. In the STEP 1 trial of semaglutide 2.4 mg for weight management, published in the New England Journal of Medicine in 2021, participants without diabetes had a mean change in body weight of −14.9% versus −2.4% with placebo over 68 weeks, as reported by the study authors. That figure describes the approved drug studied under trial conditions — it is a study finding, not a promise of any individual result, and not a claim about compounded preparations.

There are no equivalent large trials of compounded semaglutide. Compounded products are not required to demonstrate bioequivalence to the approved drug, and their potency, purity, and absorption are not independently established the way an approved product's are. So while the underlying molecule is well studied, a compounded version's performance and safety profile cannot simply be assumed to match the label data. This gap is one of the central reasons regulators urge caution.

This article does not diagnose, treat, or recommend any medication. Decisions about GLP-1 therapy — including whether any form is appropriate — should be made with a licensed clinician who can assess your full medical history. GLP-1 medications carry labeled warnings and contraindications (for example, the approved labels carry a boxed warning regarding thyroid C-cell tumors based on rodent studies and advise against use in people with a personal or family history of medullary thyroid carcinoma or MEN 2).

Whether a telehealth platform is a good choice comes down to transparency. Use these questions — a trustworthy provider will answer them plainly:

1. Is there a real consultation with a licensed provider? A prescription should follow an evaluation by a clinician licensed in your state, not a checkbox form. Ask whether you can speak with the prescriber.
2. Are you prescribing FDA-approved semaglutide or a compounded version? If compounded, ask why — and on what legal basis it's being compounded now that the shortage is resolved.
3. If compounded, which pharmacy makes it, and is it 503A or 503B? Get the pharmacy's name and state. You can verify licensure with the state board of pharmacy and check the FDA's registered outsourcing-facility list for 503B.
4. What is the active ingredient — semaglutide base, or a salt form? If the answer is sodium or acetate salt, that is the FDA-flagged formulation issue above.
5. Can I see a Certificate of Analysis (COA) for the product or lot? Independent third-party testing for potency, purity, and sterility is a meaningful signal. "We can't share that" is itself an answer.
6. How is the medication supplied and dosed? Prefilled pens reduce measurement error; multi-dose vials with syringes put dosing accuracy on you. Ask for clear instructions and clinician support.
7. What are the total costs and what happens if I stop? Get pricing in writing and confirm whether it's a subscription. (Pricing varies by provider and changes often — always verify current pricing at the source.)
8. Who do I contact for side effects, and is there ongoing clinical follow-up? Continuity of care matters; this is medication, not a supplement.

Among providers that operate in this space, some emphasize FDA-approved products or manufacturer-direct fulfillment (for example, telehealth services that route eligible patients to NovoCare or LillyDirect for branded medication), while others have offered compounded options through named pharmacies. The right answer for you depends on eligibility, cost, and your clinician's judgment — not on marketing.

This content is for educational purposes and is intended for adults 18 and older. It is not medical advice and does not replace consultation with a qualified healthcare professional. A prescription medication requires evaluation by, and a prescription from, a licensed provider. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. GLP-1 Samples does not sell, ship, prescribe, or dispense medication; we provide independent editorial information and may link to licensed telehealth providers. Any prices mentioned are attributed to the provider and change frequently — always verify current pricing and terms at the source. Never obtain prescription medication without a prescription or from sellers marketing "research chemicals" or products "not for human consumption."